Protara Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Protara Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 97% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 90% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.1 times its market value (net cash). Higher than 89% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-642.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 97% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-45.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 71% of Healthcare companies in United States.
Cash Cushion Ratio
1.1× cashCash, after subtracting all debt, is 1.1 times its market value (net cash).
Higher than 89% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 87% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 90% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Protara Therapeutics, Inc. made a loss over the last year. Protara Therapeutics, Inc. owes $0.08 for every $1 it owns. Protara Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossProtara Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.85The share price is 0.85 times Protara Therapeutics, Inc.'s book value per share, lower than 82% of Healthcare companies in United States.
Market cap
$138 MThe total market value of all of Protara Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 62% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$161 MWhat Protara Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.73Net worth divided by the number of shares. The share price of $2.33 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-45.8%Protara Therapeutics, Inc. lost 45.8% of its shareholders' money over the last year, higher than 52% of Healthcare companies in United States.
Owes vs Owns
0.08×Protara Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 89% of Healthcare companies in United States.
Dividend yield
NoneProtara Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossProtara Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashProtara Therapeutics, Inc. held $152 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Protara Therapeutics, Inc.: $138 M ÷ $161 M (30 Jun 2026) = 0.9.
What is Protara Therapeutics, Inc.'s return on equity?
Protara Therapeutics, Inc. lost 45.8% of its shareholders' money over the last year, higher than 52% of Healthcare companies in United States.
How much does Protara Therapeutics, Inc. owe compared with what it owns?
Protara Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 89% of Healthcare companies in United States.
Does Protara Therapeutics, Inc. pay a dividend?
No. Protara Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.